Synvisc OA Therapy Boosts Margins, Holds Promise For New Indications
This article was originally published in The Gray Sheet
Executive Summary
Genzyme's recent reacquisition of marketing rights to the Synvisc knee osteoarthritis treatment will help the firm realize a hefty gross margins increase in 2005